The Bull Case For Guardant Health (GH) Could Change Following Japan’s ENHERTU Approval Using Its AI Data

• In late March 2026, Guardant Health reported that real-world evidence from its InfinityAI and Guardant360 platforms helped support Japan’s approval of Daiichi Sankyo’s ENHERTU for treating certain advanced or recurrent HER2‑positive solid tumors when standard therapies fail.
• This use of Guardant’s clinicogenomic data as supplemental evidence in a national regulatory decision highlights how its AI‑driven real‑world datasets are becoming directly embedded in oncology drug approvals across multiple tumor types.
• We’ll now examine how Guardant’s InfinityAI role in Japan’s ENHERTU approval could influence the company’s investment narrative around AI‑enabled oncology data.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Guardant Health Investment Narrative Recap

To own Guardant Health, you need to believe its AI rich oncology data and liquid biopsy tests can translate into durable demand across screening, therapy selection, and biopharma partnerships, despite continued losses and heavy cash burn. The InfinityAI role in Japan’s ENHERTU approval reinforces the value of Guardant’s data asset, but does not materially change the near term focus on Shield reimbursement progress and the ongoing risk that high R&D and SG&A spending delay any path toward profitability.

The recent Verana Health partnership is especially relevant here, because it pairs Guardant’s clinicogenomic data with large scale, curated electronic health records. Together with the ENHERTU decision, this deepens Guardant’s position in AI enabled real world evidence for oncology, which sits alongside key catalysts such as Shield’s global rollout and new companion diagnostic uses, but also heightens execution risk around turning this growing data footprint into sustainable, higher margin revenue.

Yet even as InfinityAI gains traction in drug approvals, investors should be aware that Guardant’s continued cash burn and negative equity position could...

Read the full narrative on Guardant Health (it's free!)

Guardant Health's narrative projects $2.1 billion revenue and $107.1 million earnings by 2029.

Uncover how Guardant Health's forecasts yield a $130.64 fair value, a 52% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming roughly 36 percent annual revenue growth to about US$2.3 billion by 2028, so this ENHERTU win may either reinforce their view that InfinityAI can drive sustained oncology demand or highlight how exposed that thesis is to any stumble in real world evidence adoption and Shield reimbursement, reminding you that reasonable investors can read the same data very differently.

Explore 5 other fair value estimates on Guardant Health - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Guardant Health research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Guardant Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Guardant Health's overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 25 companies in the world exploring or producing it. Find the list for free.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com